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Abstract
Background: Patients with possible radiation induced cancer could be used to study if the rate of
tumour cell proliferation is related to latency time. Such a finding could help researcher to find time
periods when other initiating risk factors operate.
Methods: Seventeen women with breast cancer, with a prior history of radiation treatment
towards the parts or the whole breast, exclusive of the primary treatment of a breast cancer were
identified. Most women had received treatment for benign disorders as hemangiomas, shoulder
pain or skin infections. Three patients had been treated with mantle radiation for Hodgkin's disease
prior to developing breast cancer. DNA analysis were performed, on remaining tumour tissue after
hormone receptor analysis had been done, measuring the fraction of tumour cells in S-phase.
Latency time (time between diagnosis and previous radiation treatment) was calculated and related
to the S-phase fraction.
Results: A significant inverse relationship between latency time and S-phase was found (p <
0.0025), indicating that tumours with a high S-phase had a short latency time and vice versa. Among
the possible radiation induced tumours, median S-phase was 14%, comparable with a median
latency time of 22 years. Very high S-phase values were associated with short latency times (eg a
S-phase of 35% would be compatible with a latency time of 7 years).
Conclusion: Our preliminary results indicate that S-phase is related to latency time and that the
median latency time maybe as long as 22 years. Our data may also explain why breast cancer is rare
before 30 years of age and if patients are diagnosed at early ages, tumours often show high S-phase
values and bad prognostic signs. We postulate that these results from radiation induced breast
cancer may be used to extrapolate possible latency times in patients with non radiation induced
breast tumours in order to isolate possible time periods for research after other initiating events.
Background
Ionizing irradiation is the only proven initiating factor for
human breast cancer. As such the breast, the thyroid, and
the bone marrow appear especially radiosensitive[1]. By
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investigating several important cohorts of exposed wom-
en, as those surviving atomic bomb irradiation women
given radiation therapy for the breast for acute post-par-
tum mastitis or other benign diseases, and women exam-
ined repeatedly by fluoroscopy of the chest during
treatment for pulmonary tuberculosis with artificial pneu-
mothorax, our knowledge in the field of radiation in-
duced breast cancer has increased[2]. Studies of patients,
irradiated for benign conditions or other malignancies
than breast cancer may help to describe latency times
(time from the first initiating event to diagnosis) in hu-
man breast cancer. Studies of breast cancer after exposure
to ionizing irradiation points to latency times between
10–30 years [3–5]. In general radiation exposures at very
young ages have been associated with longer latency times
for breast cancer than exposure at higher ages because ra-
diation induced tumours generally first appear when the
normal incidence of tumour is seen [6]. Excess risk has not
appeared until 10 years after exposure and rarely before
age 30 [2,7–9]. Also the relative risk of diagnosing a tu-
mour seems to further increase in age groups where the
natural incidence is high [6]. The risk has foremost and
first been shown for women therapeutically irradiated at
young ages (childhood, adolescence), while peri- and
postmenopausal women irradiated for breast cancer in
one breast have not conclusively been found to have a
higher risk for contralateral breast cancer because of the
radiation treatment [10,11]. This could be due to the fact
that the breast epithelium at older ages is less sensitive due
to involution and less proliferation.
Cases previously irradiated for benign conditions are be-
coming less common as the indications for irradiation of
non tumour conditions are disappearing. We have previ-
ously described a case series in whom women in the past
were irradiated for various benign conditions and other
malignant diseases (as Hodgkin's disease)[12]. In that
previous study, we found that cases with the progesterone
receptor positive tumours more often had a history of
therapeutic irradiation towards parts of or the whole
breast after a pregnancy than before. Women with radia-
tion treatment before the first pregnancy instead more of-
ten had progesterone receptor negative tumours.
The aim of the present study was to see if the S-phase frac-
tion (SPF), knowing the age of the woman at diagnosis,
could predict the possible latency time and thus give in-
formation at what age or age interval the tumour ought to
have been initiated. If SPF could be used in such manner
epidemio-logical studies using markers for proliferation
in the tumour may assist the epidemiologist in designing
studies aimed at identifying initiating factors of breast
cancer in a relevant age period of life.
Methods
Seventeen women with breast cancer, with a prior history
of radiation treatment towards part of or the whole breast,
exclusive of the primary treatment of a breast cancer, were
identified. Fourteen women had received treatment for
benign disorders as hemangiomas, shoulder pain or skin
infections. Three patients had been treated with mantle ra-
diation for Hodgkin's disease prior to developing breast
cancer. The radiation dose to the breast tissue varied be-
tween 1–40 Gy. All women also had remaining tumour
tissue stored at to our department after hormone receptor
analysis had been done.
Flow cytometric DNA analysis (FCM) was performed ac-
cording to the following protocol. Tissue was stored at -
80°C and a nuclei suspension was prepared with a one-
step procedure[13,14] according to current protocol at
our lab [15]: 100–200 mg of tissue per tumour sample
was thawed in 100–200 ul of citrate buffer (sucrose 250
mM, trisodium citrate 40 mM, dimethyl sulphoxide 5%,
pH 7.6) containing trout and chicken red blood cells
(106/ml). The tissue was mechanically disintegrated with
forceps and thereafter 2 ml of a nuclear isolation medium
containing propidium iodide (PI) was added (50 mg PI/
ml, SIGMA P-5264; RNAse 0.1 mg/ml, SIGMA R-5125;
Nonidet P-40 0.6% (v/v; SIGMA N-3516) in isotonic buff-
ered saline; GIBCO). Before incubation in the dark (10
min at room temperature), the sample was filtered (nylon
mesh 140 um) in order to remove tissue remnants from
the obtained nuclei suspension. The samples were then
Figure 1BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/11
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kept at +4 C° until the analysis. An Ortho 50H flow cy-
tometer (Ortho Instruments, Westwood, Massachusetts,
USA) was used for the nuclear DNA content analysis. The
obtained DNA histogram distributions were judged either
as DNA diploid (one cell population) or DNA non-dip-
loid (two or more cell populations). By assuming the cell
population to asynchroneously synthesizing the DNA,
rectangular distribution, the fraction of cells in the S phase
(SPF) was estimated planimetrically according to Baisch et
al [16]. In case of bimodality in the DNA diploid region
reflecting near diploidy (hypo- or hyper diploidy) a mean
SPF value was reported for both cell populations together.
If DNA index of the non diploid cell population exceeded
1.3 the SPF was reported for this cell population alone.
When two or more non diploid cell populations were seen
(multiploidy) the SPF for the most prominent cell popu-
lation was calculated. In those multiploid cases where the
cell populations did not appear separated, a mean SPF val-
ue was calculated. SPF was not calculated if the histogram
showed a debris distibution pattern grossly influencing
the S phase region or the fraction of non diploid G0/
G1nuclei was less than 15% of all observed histogram
events of the cell cycle. Furthermore, SPF was not reported
for those cell populations lacking a visible G2 peak or the
CV (coefficient of variation) of the G0/G1 peak exceeded
8 %. Aggregates from nuclei were gated out using the
build in DNA analysis software of the Ortho 2140 data
handling system.
Latency time (time between diagnosis and previous radia-
tion treatment) was calculated and related to the SPF by
regression analysis testing for a linear or a nonlinear
relationship.
Results
Median age at radiation exposure was 34 years, range 1–
72 yers and median age at breast cancer diagnosis was 64
years range 39–79 years.
The median SPF was 15 (range 3.0–34%). Latency time
varied with a median 22 years (range 7–59 years)
A significant inverse relationship between latency time
and S-phase was found (p < 0.0025), see Figure 1. A linear
relation with latency time as the dependent variable and
SPF as the independent variable best fitted the values, Y =
45.89 - 1.09X, with a r2 = 0.47. An increase of one percent
in S-phase decreased latency time on average with one
year (95% confidence interval 0.5–1.73 years). A quadrat-
ic model gave a slightly better fit, r2 = 0.60, but in view of
the small number of observations it was not possible to
further explore the functional relationship in more detail
and for the same reasons prediction intervals was not pre-
sented. Data visualised in Figure 1 suggested that a latency
times less than 8 years was difficult to reach as well as SPF
levels below 3%.
No significant relationship was seen between radiation
dose and latency time (p = 0.30).
Discussion
The time of initiation of an individual breast cancer can
only rarely be assessed. The only known exogenous expo-
sure that can be used to possibly date the first initiating
event of human breast cancer is ionizing radiation. The
practise to treat benign disorders with radiotherapy was
prevalent in the past but has become more and more un-
common during the last 30 years. Especially long term
side effects as secondary tumors have discouraged the use
of radiotherapy for non tumour diagnoses. This also
means that the cohort of women, who previously has
been exposed to ionising radiation treatment for benign
diseases, is an "out dying" cohort and the time period
when it is possible to use the cohort for important biolog-
ical studies is gradually disappearing. In our setting we
were fortunate to have a population based breast tumour
bank for biological studies that was started 1979 where re-
maining tumour specimens after hormone receptor anal-
ysis have been saved as frozen specimens in -80°C.
Attempts have been made before to calculate latency
times in breast cancer using various types of subpopula-
tions as survivors of atomic bombs who later develop
breast cancer and populations previously exposed to radi-
ation treatment. The proposed latency time ranges from
10–30 years [1,17–19]. However the increased risk after
achieved minimal latency time seems to stay elevated
throughout life [20].
By comparing the SPF with the latency time in our study a
clear inverse relationship appeared. Our preliminary re-
sults indicate that by using the SPF it would be possible in
larger materials to predict latency time and that the medi-
an latency time maybe as long as 22 years. In men with
possible radiation induced breast cancer a possible laten-
cy time of 30–40 years have been suggested [4]. Also a
minimum latency time of 8 years has been suggested out
from radiation exposure studies and breast cancer [5]. In
women, irradiated between the time of puberty and the
age of 30 for Hodgkin's disease, a median latency time of
15 years have been seen [21,22]. Our results are not con-
tradictory to these previous findings. The data may also
explain why breast cancer is rare before 30 years of age as
a tumour with a high SPF of 20% still would on average
take 25 years to develop. Further data on SPF and latency
time also give an explaination for findings of tumour bi-
ology in the very young women. For such a tumour to ap-
pear with a latency time less than 30 years there is a need
to have a SPF above 20% and this tumour necessarilyBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/11
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needs to show bad prognostic signs as a high SPF has been
related to poor prognosis [23]. Studies on breast cancer
prognosis in different age groups have especially singled
out women below age 35 as having a worse prognosis
than other women [24–26]. The breast tumours in pa-
tients with a prior history of Hodgkin's disease also seem
to be more aggressive giving the patients a poorer survival
in line with a possibility of higher SPF of their primary tu-
mours because of the rather short latency time [27].
These latency times for radiation induced breast cancer ac-
cord very well with time studies of breast cancer develop-
ment from atypical hyperplasia, through ductal
carcinoma in situ and to invasive carcinoma, thought to
require 10–20 years or more [28,29].
The median SPF in larger investigations at our laboratory
is around 11% [30] compared to the result of the present
investigation's 14%. The variation can easily be explained
by our small sample size of possibly radiation induced tu-
mours. As the SPF varied between 3–34% a difference in
latency time between tumours could be as large as 7–59
years (median 22 years).
A shortcoming in our investigation is that while epidemi-
ological data support that the group of patients may have
radiation treatment as a risk factor it is impossible in the
individual case to for certain know if radiation caused the
tumour. We speculate that if we could accurately know
which tumours that were radiation induced, the fit of the
model would have been near perfect using the SPF.
We can not fully exclude that the model e.g. is quadratic
rather than linear. More cases with biological data would
be needed to fully describe the true relationship, but it is
reasonable to believe that a minimal latency time of 5–10
years is required for a breast cancer to be able to develop.
The reproducibility of analysing the SPF is in our hands
very high [31,32] and there is a high correlation with oth-
er measures of proliferation [33]. Further SPF calculations
give very good prognostic information [23,30]. However
there are sometimes potential problems as in patients
with low SPF and multiple tumour populations calcula-
tions can be contaminated with normal tissue from tu-
mour stroma or inaccuracies can occur in assessing the
SPF because of overlapping tumour cell populations [30].
Other potential problems by our approach of relating the
SPF to latency time is that cell loss/cell death in individual
tumours could not be estimated or accounted for and may
vary between tumours. Further it is not fully known from
literature how human tumours grow eg if there is a conti-
neous linear growth, exponential growths according to
Gompertz or periods of interrupted exponential growths
[34]. Further in experimental tumours there is a sugges-
tion that a higher radiation dose may be related to a short-
er latency time. However, this has been proposed to be
due to a higher statistical probability for transformation at
higher doses [35]. In the present study we did not see a
statistical significant relationship between radiation dose
and latency time, but the small sample size could have
prevented us from finding a significant association. In
general it has also been stated that radiation induced tu-
mours in man tend to present at common ages for the in-
cidence of a given tumour and thus be related to longer
latency times if the radiation exposure took place at
younger ages [36].
Most breast cancers are thought to start its development
early in life at puberty or even in early childhood or in ute-
ro [37]. Previously, it has been proposed from one of the
authors that the tumour at diagnosis, at least partially, re-
tains characteristics of the normal breast epithelium at the
time of initiation and that varying tumour biology/prog-
nosis at different ages may be explained out from this
[38,39]. Experience from atom bomb survivors suggest
that reproductive factors and hormone use appear to act
independently of radiation exposure on the risk of breast
cancer among this population [40].
Conclusion
Results from radiation induced breast cancer may be used
to extrapolate possible latency times in patients with non
radiation induced breast tumours. Out from a woman's
age at diagnosis and SPF, a possible latency time, using
our linear formula, possibly can be predicted and initiat-
ing epidemiological risk factors can be sought in the re-
sponsible time period for initiation. This may enable
researcher to more efficiently find new initiating risk fac-
tors of breast cancer. It is conceivable that other measures
of tumour proliferation rate as mitotic index, labelling in-
dex, antibodies as Ki-67, or BrdU labelling may be used in
a similar manner and this may allow studies on larger pa-
tient materials, where paraffin embedded tumour materi-
als have been saved. These different measures of
proliferation (such as S-phase, labelling index, mitotic in-
dex, Ki-67) have been found to correlate well with each
other in breast cancer [41]. To calibrate curves between tu-
mour proliferation rate and latency time, tumours from
possibly radiation induced cases must be identified and
used. Therefore radiation induced cases consitute a very
important "out-dying" research source.
References
1. Ullrich R Etiology of Cancer:Physical Factors In: Cancer. Principles
& Practice of Oncology (Edited by: de Vita V, Hellman S, Rosenberg S) Phil-
adelphia: Lippincott Williams & Wilkins 2001, 195-206
2. Boice J, Land C and Preston D Ionizing radiation In: Cancer Epide-
miology and Prevention (Edited by: Schottenfeld D, Fraumeni J) New York:
Oxford University Press 1996, 319-354
3. Thomas D Epidemiologic and related studies of breast cancer
etiology In: Reviews in cancer epidemiology (Edited by: Lilienfeld A) New
York: Elsevier/North-Holland 1980, 153-217Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/11
Page 5 of 5
(page number not for citation purposes)
4. Thomas DB, Rosenblatt K, Jimenez LM, McTiernan A, Stalsberg H,
Stemhagen A, Thompson WD, Curnen MG, Satariano W and Austin
DF  Ionizing radiation and breast cancer in men (United
States) Cancer Causes Control 1994, 5:9-14
5. Goss PE and Sierra S Current perspectives on radiation-in-
duced breast cancer J Clin Oncol 1998, 16:338-47
6. Upton AC Carcinogenic effects of ionizing radiation In: Mecha-
nisms of carcinogenesis (Edited by: Weisburger EK) Dordrecht, Nether-
lands: Kluwer Academic Publishers 1989, 54-70
7. Tokunaga M, Norman JE Jr, Asano M, Tokuoka S, Ezaki H, Nishimori
I and Tsuji Y Malignant breast tumors among atomic bomb
survivors, Hiroshima and Nagasaki, 1950–74 J Natl Cancer Inst
1979, 62:1347-59
8. Kato H Radiation-induced cancer and its modifying factor
among A-bomb survivors Princess Takamatsu Symp 1987, 18:117-
24
9. Ron E Ionizing radiation and cancer risk: evidence from
epidemiology Radiat Res 1998, 150:S30-41
10. Boice JD Jr Radiation and breast carcinogenesis Med Pediatr
Oncol 2001, 36:508-13
11. Jung H Is there a real risk of radiation-induced breast cancer
forpostmenopausal women? Radiat Environ Biophys 2001, 40:169-
74
12. Olsson H, Sigurdsson H, Borg Å and Fernö M Relationship of pro-
gesterone-receptor positivity in malignant breast tumours
to reproductive status of women at tumour initiation-results
from patients with possible radiation induced tumours J Natl
Cancer Inst 1990, 82:529-531
13. Thornthwaite J, Sugarbaker E and Temple W Preparation of tis-
sues for DNA flow cytometric analysis Cytometry 1980, 1:229-
237
14. Lee G, JT T and Rasch E Picogram per cell determination of
DNA by flow cytofluorometry Analyt Biochem 1984, 137:221-226
15. Baldetorp B, Dahlberg M, Holst U and Lindgren G Statistical eval-
uation of cell kinetic data from DNA flow cytometry (FCM)
by the EM algorithm Cytometry 1989, 10:695-705
16. Baisch H, Göhde W and Linden W Analysis of PCP-data to deter-
mine the fraction of cells in the various phases of cell cycle
Radiat Environ Biophys 1975, 12:31-39
17. Hildreth N, Shore R and Dvoretsky P The risk of breast cancer
after irradiation of the thymus in infancy N Engl Journ Med 1989,
321:1281-1284
18. Modan B, Alfandary E, Chetrit A and Katz L Increased risk of
breast cancer after low-dose irradiation Lancet 1989, i:629-631
19. Shore RE Electromagnetic radiations and cancer. Causes and
prevention Cancer 1988, 62:1747-1754
20. Mattsson A, Ruden BI, Palmgren J and Rutqvist LE Dose- and time-
response for breast cancer risk after radiation therapy for
benign breast disease Br J Cancer 1995, 72:1054-61
21. Cutuli B, de La Rochefordiere A, Dhermain F, Borel C, Graic Y, de
Lafontan B, Dilhyudy JM, Mignotte H, Tessier E, Tortochaux J, N'Guy-
en T, Bey P, Le Mevel-Le Pourhier A and Arriagada R [Bilateral
breast cancer after Hodgkin disease. Clinical and pathologi-
cal characteristics and therapeutic possibilities: an analysis of
13 cases] Cancer Radiother 1999, 1:300-6
22. Clemons M, Loijens L and Goss P Breast cancer risk following ir-
radiation for Hodgkin's disease Cancer Treat Rev 2000, 26:291-
302
23. Wenger CR and Clark GM S-phase fraction and breast cancer –
a decade of experience Breast Cancer Res Treat 1998, 51:255-65
24. Höst H and Lund E Age as a prognostic factor in breast cancer
Cancer 1986, 57:2217-2221
25. Adami H, Malker B, Holmberg L, Persson I and Stone B The relation
between survival and age at diagnosis in breast cancer N Engl
J Med 1986, 315:559-563
26. Guinee V, Olsson H, Möller T, Hess K, Taylor S, Fahey T, Gladikov J,
van den Blink J, Bonichon F, Dische S, Yates J and Cleton F Effect of
pregnancy on prognosis for young women with breast cancer
Lancet 1994, 343:1587-89
27. Gaffney DK, Hemmersmeier J, Holden J, Marshall J, Smith LM, Avi-
zonis V, Tran T and Neuhausen SL Breast cancer after mantle ir-
radiation for Hodgkin's disease: correlation of clinical,
pathologic, and molecular features including loss of hetero-
zygosity at BRCA1 and BRCA2 Int J Radiat Oncol Biol Phys 2001,
49:539-46
28. Frykberg E and Bland K In situ breast cancer Adv Surgery 1993,
26:29-72
29. Page DL, Dupont WD, Rogers LW and Rados MS Atypical hyper-
plastic lesions of the female breast. A long-term follow-up
study Cancer 1985, 55:2698-708
30. Sigurdsson H Indicators of prognosis in breast cancer Oncology
Lund: Lund 1990, 68
31. Gudmundsson TE, Langstrom E, Alm P, Anderson H, Baldetorp B,
Ferno M, Hogberg T and Killander D Methodological aspects of
flow cytometry DNA analysis in endometrial carcinoma,
with special reference to sampling and reproducibility Acta
Oncol 1996, 35:999-1006
32. Baldetorp B, Stal O, Ahrens O, Cornelisse C, Corver W, Falkmer U
and Ferno M Different calculation methods for flow cytomet-
ricS-phase fraction: prognostic implications in breast can-
cer? The Swedish Society of Cancer Study Group Cytometry
1998, 33:385-93
33. Rudolph P, Olsson H, Ratjen V, Bolte H, Baldetorp B, Fernö M, Par-
waresch R and Alm P Correlation between p53, C-erbB-2, and
topoisomeras II expression, DNA ploidy, hormonal receptor
status and proliferation in node negative breast cancer.
Prognostic implications J Pathology 1999, 187:207-216
34. Harris J and Hellman S Natural history of breast cancer In: Dis-
eases of the Breast (Edited by: Harris J, Lippman M, Morrow M, Hellman
S) Philadelphia: Lippincott-Raven Publishers 1996, 375-391
35. Guess HA and Hoel DG The effect of dose on cancer latency
period J Environ Pathol Toxicol 1977, 1:279-86
36. Boice J Risk estimates for breast cancer In: Critical issues in setting
radiation dose limits. Proceedings of the 7th Annual meeting 8–9th April:
7910 Woodmont Ave (Edited by: N. C. o. R. P. a. Measurements) Bethesda
Md 20814 1981, 164-181
37. Kelsey J Epidemiology of breast cancer Epidemiol Rev 1993, 15:1-
236
38. Olsson H A hypothesis about the tumour development and
clinical picture in hereditary breast cancer Eur J Cancer 2001,
37:2023-2029
39. Olsson H Tumour biology of a breast cancer at least partly re-
flects the biology of the tissue/epithelial cell of origin at the
time of initiation – a hypothesis The Journal of Steroid Biochemistry
& Molecular Biology 2000, 74:345-350
40. Goodman MT, Cologne JB, Moriwaki H, Vaeth M and Mabuchi K Risk
factors for primary breast cancer in Japan: 8-year follow-up
of atomic bomb survivors Prev Med 1997, 26:144-53
41. Clark GM Prognostic and predictive factors In Diseases of the
Breast (Edited by: Harris, JR, Lippman ME, Morrow M, Hellman S) Lippin-
cott-Raven Publishers, Philadelphia 1996, 461-485
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/3/11/prepub